Methylphenidate Plus GWI-Nutrient Formula as a Treatment for Patients With Gulf War Illness

Status unconfirmed · Phase 2

Conditions studied: Gulf War Illness

In brief

The Gulf War Synergy Trial will evaluate the safety and efficacy of a currently available medication, methylphenidate (Ritalin®), combined with a GWI Nutrient Formula (K-PAX Synergy) to treat Gulf War Illness (GWI).

Key facts

Study ID
NCT02357030
Run by
K-PAX Pharmaceuticals, Inc.
People needed
30
Starts
2015-01-01
Expected to finish
2016-05-01
Last updated by the study team
2015-10-15

Who can join

Age: 18 and older, up to 64. Sex: any. Healthy volunteers: not accepted.

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.